A team led by researchers from the Indiana University School of Medicine has identified a protein present in the brains of individuals with frontotemporal dementia (FTD), unveiling a promising target for potential treatments. Frontotemporal dementia, characterized by neuron damage in the frontal and temporal lobes, manifests symptoms such as unusual behaviors, emotional challenges, communication difficulties, and impaired motor functions, typically emerging between ages 25 and 65.
Neurodegenerative disorders like FTD and ALS occur when specific proteins form amyloid filaments in nerve cells. In this case, the protein TAF15 was identified as the culprit behind amyloid filaments in the brain and spinal cord cells of FTD patients.
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
In addition to identifying TAF15 using neuropathologic and molecular techniques, the study published in Nature, also utilized cryo-electron microscopy to reveal the structure of TAF15 amyloid filaments.
According to lead neuropathologist Bernardino Ghetti, “This discovery represents an important breakthrough that recognizes TAF15 as a potential target for the development of diagnostic and therapeutic strategies toward a lesser-known form of frontotemporal lobar degeneration associated with frontotemporal dementia.”